Dr. Aditya Bardia and Dr. Reena Callahan – Redefining HER2 Classifications and Treatments

In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases. From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 classifications, have moved on from binary to a continuum from low to even ultra-low expression and are reshaping therapeutic paradigms and patient care decisions. Key insights into managing brain metastases, T-DXd associated pneumonitis, optimizing treatment sequencing, and effectively communicating complex medical data to patients highlight the conversation. This episode is essential listening for oncologists, researchers, and advocates interested in the latest shifts in breast cancer therapy.

Topics Covered:
• Historical evolution of HER2 classifications
• Clinical impact of HER2 low and ultra-low categorizations
• DESTINY-Breast trials and groundbreaking T-DXd data
• Management strategies for brain metastases, T-DXd associated pneumonitis
• Patient-centered communication and shared decision-making